Taisho Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Loqoa · Immunology
• Nanozora · Oncology

Phase 3 pipeline

• Diclofenac diethylamine · Pain Management, Rheumatology, Inflammation
  Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
• Placebo to TS-142
  TS-142 is a drug with an unknown mechanism of action.
• TS-152 · Diabetes
  TS-152 is a small molecule that targets the SGLT2 receptor.
• TS-172 · Psychiatry
  TS-172 is a small molecule that targets the serotonin receptor.

Phase 2 pipeline

• Step 1: TS-142
• Step 2: TS-142
• TS-142

Phase 1 pipeline

• [14C] TS-142
• [14C] TS-172
• PF-04802540
• Triazolam and TS-172
• TS-091
• TS-143
• TS-172 and itraconazole

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Taisho Pharmaceutical Co., Ltd. portfolio CI brief
• Taisho Pharmaceutical Co., Ltd. pipeline updates RSS